Hepatitis B Virus (HBV) Market Report 2026

The hepatitis b virus (hbv) market size has grown strongly in recent years. It will grow from $7.31 billion in 2025 to $7.98 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to high prevalence of hbv in asia-pacific, limited awareness about hbv treatment, low vaccination coverage in early years, reliance on generic antiviral drugs, rising incidence of chronic liver disease.

The hepatitis b virus (hbv) market size is expected to see rapid growth in the next few years. It will grow to $11.77 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to increasing r&d in hbv therapeutics, expansion of government vaccination programs, adoption of precision medicine, rising healthcare expenditure, growth in screening and diagnostic infrastructure. Major trends in the forecast period include increasing adoption of antiviral therapies, rising hepatitis b vaccination programs, development of combination therapies, focus on pediatric and geriatric hbv management, expansion of screening and diagnostic services.

The high prevalence of hepatitis B infection is expected to drive the growth of the hepatitis B virus market in the coming years. Hepatitis B is a liver infection caused by the hepatitis B virus (HBV) and can be prevented through vaccination. Rising rates of hepatitis B infection can increase demand for diagnostic tests and treatment options. For instance, the Centers for Disease Control and Prevention (CDC), a US-based national public health agency focused on disease control and prevention, estimated 13,300 new hepatitis B infections and 69,800 new hepatitis C infections in 2023. Therefore, the high prevalence of hepatitis B infection is propelling growth in the hepatitis B virus market.

Major companies in the HBV market are focusing on advancing innovative therapies through clinical trials and accelerating regulatory progress to improve treatment outcomes and gain a competitive edge. For instance, in August 2025, Aligos Therapeutics, a US-based therapeutics company, began dosing patients in its Phase II B-SUPREME trial evaluating ALG-000184, a first-in-class oral capsid assembly modulator for chronic hepatitis B. This randomized, double-blind study will enroll approximately 200 treatment-naïve adults, comparing ALG-000184 to tenofovir disoproxil fumarate over 48 weeks. The primary goal is to reduce HBV DNA levels below quantifiable limits in both HBeAg-positive and HBeAg-negative participants, while secondary measures assess safety, pharmacokinetics, and antigen changes. Earlier Phase I data demonstrated strong antiviral activity and good tolerability, supporting the drug’s potential. Interim results are expected in 2026, with full topline findings anticipated in 2027.

In July 2023, Brii Biosciences Ltd., a China-based biotechnology company, acquired licensing rights for an experimental hepatitis B immunotherapy and an approved hepatitis B vaccine from VBI Vaccines Inc. for an undisclosed amount. This acquisition provides Brii Biosciences Ltd. with access to technologies for both the prevention and treatment of hepatitis B. VBI Vaccines Inc. is a US-based biotechnology company engaged in developing a vaccine to prevent infection caused by the hepatitis B virus.

Major companies operating in the hepatitis b virus (hbv) market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sanofi SA, GlaxoSmithKline PLC, Gilead Sciences Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Apotex Corp., Lupin Pharmaceuticals Inc., Cadila Healthcare Ltd., Dynavax Technologies Corporation, Accord Healthcare Inc., Par Pharmaceutical Inc., Arbutus Biopharma Corporation, Antios Therapeutics Inc.

North America was the largest region in the hepatitis B Virus (HBV) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis b virus (hbv) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hepatitis b virus (hbv) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the hepatitis b virus market by affecting the cost and availability of antiviral drugs, vaccines, and diagnostic equipment, particularly in regions reliant on imports such as asia-pacific and latin america. The increased cost of imported pharmaceuticals and medical devices has impacted hospitals, healthcare providers, and distributors, slowing adoption in some segments. However, tariffs have also encouraged local production of vaccines and antivirals, fostering regional manufacturing initiatives and cost optimization strategies. The chronic hbv treatment and vaccine segments are most affected, while markets with strong domestic production have seen some positive impact.

The hepatitis b virus (hbv) market research report is one of a series of new reports that provides hepatitis b virus (hbv) market statistics, including hepatitis b virus (hbv) industry global market size, regional shares, competitors with a hepatitis b virus (hbv) market share, detailed hepatitis b virus (hbv) market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis b virus (hbv) industry. This hepatitis b virus (hbv) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hepatitis B virus (HBV) is a viral infection that affects the liver and is transmitted through contact with contaminated blood or bodily fluids, or from mother to child during childbirth. Treatment involves antiviral medications to suppress viral replication, while vaccination serves as a key preventive measure.

The main types of hepatitis B virus (HBV) are acute and chronic. Acute hepatitis B is a short-term infection caused by the virus that occurs within the first six months of exposure, and medications aim to eliminate the virus and prevent progression to chronic infection. Treatments include immune modulators, antiviral drugs, vaccines, and surgery, and are administered to different age groups, including pediatric, adult, and senior patients, by medical providers, patients, and healthcare payers.

The hepatitis B virus (HBV) market consists of revenues earned by entities by providing diagnostic testing for infection and monitoring of liver function. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis B virus (HBV) market also includes sales of tenofovir disoproxil, entecavir, telbivudine and lamivudine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.